Security record · archived quarter
CPRX
Catalyst Pharmaceuticals, Inc. · Healthcare · Biotechnology
14Tracked holders
0Δ holders
15.06MShares held
$314.25MReported value
+1New positions
−1Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +1.3% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 109 | -4 | 77.02M | $2.42B | +12 | −16 |
| Q1 2026 | 116 | +4 | 78.68M | $1.95B | +8 | −4 |
| Q4 2025 | 111 | 0 | 78.17M | $1.82B | — | — |
| Q3 2025 | 19 | 0 | 48.11M | $947.78M | — | −1 |
| Q2 2025 | 17 | +1 | 43.29M | $939.35M | +1 | — |
| Q1 2025 | 13 | -1 | 14.99M | $363.56M | — | −1 |
| Q4 2024 | 14 | 0 | 15.06M | $314.25M | +1 | −1 |
| Q3 2024 | 13 | +3 | 9.07M | $180.23M | +4 | −1 |
| Q2 2024 | 10 | — | 9.29M | $143.84M | — | — |
Who holds it · Q4 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 5.80M | — | $120.97M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 2.71M | +7.1% | $56.48M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 2.67M | 0.0% | $55.64M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 2.67M | 0.0% | $55.64M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.22M | -1.5% | $25.37M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 1.22M | -1.5% | $25.37M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Arrowstreet Capital ✦ | 698.15K | +131.4% | $14.57M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Millennium Management ✦ | 520.78K | -7.0% | $10.87M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 477.01K | +3.8% | $9.96M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 477.01K | +3.8% | $9.96M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 477.01K | +3.8% | $9.96M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 436.47K | +1629.4% | $9.11M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 436.47K | +1629.4% | $9.11M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | Marshall Wace ✦ | 253.64K | -70.5% | $5.29M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Marshall Wace ✦ | 253.64K | -70.5% | $5.29M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Norges Bank ✦ (passive) | 91.77K | 0.0% | $1.92M | 0.0% | Held | 2 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 86.85K | +0.1% | $1.81M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Wellington Management ✦ | 51.55K | -13.5% | $1.08M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Wellington Management ✦ | 51.55K | -13.5% | $1.08M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Wellington Management ✦ | 51.55K | -13.5% | $1.08M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 21 | Wellington Management ✦ | 51.55K | -13.5% | $1.08M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 22 | Gotham Asset Management ✦ | 38.95K | +7.8% | $812,949 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 23 | D. E. Shaw & Co. ✦ | 18.17K | New | $379,271 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $379,271 | 0.0% |
Exited
| Two Sigma Investments | $3.17M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 378 holders, 103.75M shares, $2.50B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q4 2024 ·
Methodology ·
Get this via the API